Keyphrases
Radiotherapy
84%
Chemotherapy
60%
Tumor
50%
BRAF mutation
42%
Combination Chemotherapy
35%
Extraction Residue
34%
Actuarial Survival
32%
5-fluorouracil (5-FU)
32%
Cisplatin
31%
Non-Hodgkin Lymphoma
31%
Methanol Extraction
30%
FMR1 Premutation
29%
Israel
26%
Hebrew
25%
Northern Israel
23%
Doxorubicin
22%
Irradiation
22%
Ashkenazi
20%
Treatment Results
20%
5-year Survival
19%
Lymphoma
19%
Survival Rate
19%
Breast Cancer Patients
18%
Promoter Methylation
18%
Cancer Patients
17%
Oncology Center
17%
Retrospective Analysis
17%
Malignant Melanoma
16%
In(III)
16%
Cyclophosphamide
15%
Carcinoma
15%
RASSF1A
15%
CGG Repeat
15%
Adjuvant Therapy
15%
Hypermethylation
15%
Tumor Suppressor Gene
14%
Complete Remission
14%
Uterine Serous Carcinoma
14%
Uveal Melanoma
14%
Adriamycin
14%
Ashkenazi Jews
14%
Israeli
14%
Relative Dose Intensity
13%
Malignant Lymphoma
13%
Malignancy
13%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
13%
Papillary Thyroid Carcinoma
13%
Hodgkin Disease
13%
Methotrexate
12%
Fragile X Mental Retardation 1 (FMR1)
12%
Medicine and Dentistry
Radiation Therapy
100%
Disease
89%
Neoplasm
55%
Malignant Neoplasm
43%
Non-Hodgkin Lymphoma
27%
Methanol Extraction Residue
27%
Nodular Melanoma
25%
Recurrent Disease
24%
Survival Rate
23%
Breast Cancer
22%
Combination Chemotherapy
22%
Cisplatin
21%
Doxorubicin
20%
Carcinoma
19%
Papillary Thyroid Cancer
19%
Endometrium Carcinoma
18%
Krukenberg Tumor
17%
Oncology
16%
Adenocarcinoma
16%
Pelvis
14%
External Beam Radiotherapy
14%
Mycobacterium Bovis BCG
14%
Uterine Cervix
14%
Prostate Cancer
13%
Side Effect
13%
Methylation
13%
Metastatic Carcinoma
13%
Lymphoma
13%
Fluorouracil
13%
Neck
12%
Methotrexate
12%
Cancer
12%
Adjuvant Therapy
12%
Serous Carcinoma
12%
Head and Neck Cancer
12%
Lung Cancer
12%
Symptom
11%
FMR1
11%
Promoter Region
11%
Non Small Cell Lung Cancer
10%
Uveal Melanoma
10%
Bone Marrow Biopsy
10%
Cervical Cancer
9%
Sarcoma
9%
Exon
9%
Tumor Suppressor Gene
9%
Cyclophosphamide
9%
Lymph Node
9%
Squamous Cell Carcinoma
9%
Disease Free Survival
9%